Next trial for Starpharma

By Staff Writers
Wednesday, 13 August, 2008

Melbourne's Starpharma has started a new clinical trial of VivaGel to measure the duration of antiviral activity after administration.

VivaGel is a vaginal microbicide aimed at preventing transmission of HIV and genital herpes.

Assessment will be by laboratory assay of vaginal samples collected up to 24 hours after VivaGel application. The study in 12 women will determine the timescale over which VivaGel retains activity against HIV and HSV-2 (genital herpes).

"The value of this short trial is that it provides a potential surrogate for antiviral efficacy of VivaGel in humans ahead of Phase III studies," Starpharma's CEO Dr Jackie Fairley said. "It will also give an indication of just how long before sex you could apply VivaGel to prevent infection."

The study is being conducted at the Centre for Clinical Studies in Melbourne and is funded by the US National Institutes of Health (NIH).

Related News

Sleep apnoea patients who use CPAP live longer: study

CPAP therapy has been found to significantly reduce the risk of death for people with obstructive...

Does exercise really extend lifespan? It's complicated

Physical activity is seen as a way to extend the human lifespan, but the benefits of physical...

Nature helps to relieve physical pain

Experiencing nature, even in the form of watching nature videos, can alleviate acute physical pain.


  • All content Copyright © 2025 Westwick-Farrow Pty Ltd